Kantar Health Blog

  • Neesha Suvarna
    Oncology Conference Insight: AACR - Final progression-free survival (PFS) data from the PALOMA-1 phase II trial was presented at the Plenary Session of the 2014 American Association for Cancer Research (AACR; Finn, abstract CT-101). Observers were expecting positive news, since interim analyses already had shown PFS benefit for palbociclib (PD 0332991, Pfizer/Amgen/Onyx) and Pfizer had indicated via press release that the final PFS results were positive (February 3, 2014).
    Continue Reading > | Go comment! | Share
  • The Evolving Use of White Bagging in Oncology

    by User Not Found | Mar 28, 2014
    User Not Found
    Channel dynamics are changing for physician-administered infusible drugs, with implications for practice economics, payer utilization management, site of care, and availability of data for manufacturers. Today, buy and bill’ is the primary method of distribution of IV oncology drugs, whereby oncology practices typically purchase these drugs from specialty distributors/group purchasing organizations (GPOs), which are then billed to payers under the medical benefit.
    Continue Reading > | Go comment! | Share
  • Creating opportunity out of industry change

    by Lynnette Cooke | Mar 10, 2014
    Lynnette Cooke
    Market research is no different than any other industry. If you don’t understand and react to changes in the market, a competitor will and your business will be at risk.
    Continue Reading > | Go comment! | Share
  • Brian Mondry
    With the current influx of affordable, non-intrusive wearable technology, the Quantified Self movement is fast approaching its tipping point into the mainstream. Now that a myriad of individual vendors, consumer and pharmaceutical brands have invested heavily in the space, the technology is small and cheap enough to be accessible to the masses. This creates an opportunity to collect and evaluate biometric data on a scale that historically has been impossible.
    Continue Reading > | Go comment! | Share
  • Patricia Ensor
    One of the most debated aspects of the Affordable Care Act (ACA) is how the newly insured will use existing healthcare resources. Will they overwhelm emergency rooms? Will out-of-pocket costs continue to pose access barriers for these newly insured patients?
    Continue Reading > | Go comment! | Share